Are we ready to stratify treatment for diffuse large B-cell lymphoma using molecular hallmarks?

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Diffuse large B-cell lymphoma (DLBCL) is heterogeneous, with subtypes germinal center B-cell-like (GCB) and activated B-cell-like (ABC) having different prognoses.
• Cell-of-origin (COO) classification aids prognostication and predicts therapy response, but immunohistochemistry (IHC) methods may be less accurate than gene expression profiling (GEP).

Purpose of the Study:

• To review emerging molecular targets and novel therapeutic agents for DLBCL.
• To discuss the potential for stratifying DLBCL therapy based on molecular features.

Main Methods:

• Review of current literature on DLBCL classification, molecular mechanisms, and therapeutic strategies.
• Examination of gene expression profiling (GEP) versus immunohistochemistry (IHC) for COO classification.
• Discussion of novel technologies like next-generation sequencing in identifying pathogenic genetic aberrations.

Main Results:

• GEP is superior to IHC for classifying DLBCL COO, defining prognostically and biologically distinct subtypes.
• ABC-DLBCL is linked to NF-κB pathway activity, while GCB-DLBCL involves C-REL amplification and BCL-2/EZH2 mutations.
• New technologies are uncovering novel genetic drivers, informing targeted DLBCL treatment.

Conclusions:

• GEP offers superior DLBCL subtyping, but accessibility and standardization remain challenges.
• Understanding molecular drivers within DLBCL subtypes is crucial for developing effective, personalized therapies.
• Stratifying DLBCL treatment based on molecular features shows promise, supported by emerging evidence.